Combination therapies and real world treatment for PBC patients

This CME-accredited expert discussion aims to highlight the unmet needs in late-onset genetic cholestasis and provide guidance on the use of genetic testing in the diagnostic workup and initial management steps for the different genotypes, with reference to key trials and updates from The Liver Meeting 2024: American Association for the Study of Liver Diseases (AASLD).

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.

Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.

Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.

Drs Marlyn Mayo and Gideon Hirschfield discuss the unmet needs in PBC management, highlighting the significant burden that symptoms pose for patients, the importance of monitoring and a patient-centric management approach offering insights into what might lie ahead in 2024.

ASSURE study findings show that seladelapr elicits a biochemical response in patients with primary biliary cholangitis and cirrhosis.